Nature's Innovation, Inc. – Trademark Portfolio
Entity Type: 03
Nature's Innovation, Inc. holds 25 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 20 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 3 Nice Classification classes. Currently, 16 trademarks are registered. Notable registered marks include BENZARID, COBRAZOL, NATURASIL, ARACHNARID, and SEPTI-FLOW. The owner is based in Buford, GA.
5317 Palmero Court
Buford, GA 30518
Showing of trademarks Trademarks
Trademark Classifications
Nature's Innovation, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Nature's Innovation, Inc. have?
Nature's Innovation, Inc. has 25 U.S. trademarks filed with the USPTO. Of these, 16 registered, 5 abandoned, 4 cancelled.
What trademark classes does Nature's Innovation, Inc. file in?
Nature's Innovation, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Nature's Innovation, Inc.'s most well-known trademarks?
Nature's Innovation, Inc.'s registered trademark portfolio includes well-known marks such as BENZARID, COBRAZOL, NATURASIL, ARACHNARID, and SEPTI-FLOW. These are among 16 currently registered trademarks in the portfolio.
What is Nature's Innovation, Inc.'s trademark registration success rate?
Nature's Innovation, Inc. has a 64% trademark registration rate, with 16 out of 25 resolved applications resulting in successful registration. Currently, 0 applications are pending review.